Scarica l'app Stockscreener
0.9343
3.92%
-0.0381
Dopo l'orario di chiusura:
.93
-0.0043
-0.46%
Precedente Chiudi:
$0.9724
Aprire:
$0.9829
Volume 24 ore:
190.09K
Relative Volume:
0.29
Capitalizzazione di mercato:
$53.02M
Reddito:
$21.05M
Utile/perdita netta:
$-89.22M
Rapporto P/E:
-0.522
EPS:
-1.79
Flusso di cassa netto:
$-64.50M
1 W Prestazione:
+2.63%
1M Prestazione:
-20.15%
6M Prestazione:
-44.05%
1 anno Prestazione:
-55.72%
Intervallo 1D:
$0.9061
$0.9829
Intervallo di 1 settimana:
$0.895
$1.04
Portata 52W:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Nome
Tscan Therapeutics Inc
Settore
Industria
Telefono
857-399-9500
Indirizzo
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.9343 | 55.18M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Iniziato | BTIG Research | Buy |
| 2024-05-13 | Iniziato | Needham | Buy |
| 2023-06-22 | Iniziato | Wedbush | Outperform |
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
Analysis Recap: Will TScan Therapeutics Inc outperform its industry peersJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug Highlights: How liquid is BlackRock ESG Capital Allocation Term Trust stock2025 Pullback Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Activity Recap: Will TScan Therapeutics Inc outperform its industry peersMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Investor Mood: How does Waterstone Financial Inc perform in inflationary periodsQuarterly Market Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Financial Contrast: Urogen Pharma (NASDAQ:URGN) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
Take Profit: Is TScan Therapeutics Inc. forming bullish engulfing patternsWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
TScan Therapeutics (NASDAQ:TCRX) Shares Up 1.8%What's Next? - MarketBeat
Jobs Data: How much upside does TScan Therapeutics Inc. haveTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Is TScan Therapeutics Inc. stock risky to hold nowMarket Sentiment Report & Daily Entry Point Alerts - bollywoodhelpline.com
Aug Volume: Will TScan Therapeutics Inc stock benefit from M AJuly 2025 Momentum & Verified Stock Trade Ideas - baoquankhu1.vn
Weekly Trades: Will TScan Therapeutics Inc stock benefit from M AMarket Trend Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation - The Globe and Mail
TScan Therapeutics, Inc. Presents at J.P. Morgan Healthcare Conference - TradingView
Aug Momentum: How does TScan Therapeutics Inc score in quality rankingsEarnings Risk Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Is TScan Therapeutics Inc. stock a safe haven asset2025 AllTime Highs & Fast Gain Swing Alerts - ulpravda.ru
Is TScan Therapeutics Inc. stock dividend yield sustainableJuly 2025 Gainers & AI Driven Stock Movement Reports - ulpravda.ru
Breakout Move: How institutional buying supports TScan Therapeutics Inc stockJuly 2025 Action & Low Volatility Stock Recommendations - Bộ Nội Vụ
Institution Moves: Is TScan Therapeutics Inc. stock safe for conservative investorsOptions Play & Risk Adjusted Swing Trade Ideas - Улправда
Why TScan Therapeutics Inc. stock attracts global investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Is TScan Therapeutics Inc. stock recession proofPortfolio Risk Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
How institutional buying supports TScan Therapeutics Inc. stock2025 Trading Recap & Stepwise Trade Signal Implementation - Улправда
What risks investors should watch in TScan Therapeutics Inc. stock2025 Year in Review & Fast Exit/Entry Strategy Plans - Улправда
Why TScan Therapeutics Inc. stock is a must watch in 2025Weekly Stock Recap & Consistent Profit Trade Alerts - Улправда
Tech Rally: Why TScan Therapeutics Inc stock appeals to analysts2025 Stock Rankings & Proven Capital Preservation Methods - Bộ Nội Vụ
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Guidance Update: Why TScan Therapeutics Inc stock attracts global investorsMarket Growth Review & Verified Swing Trading Watchlist - Bộ Nội Vụ
Weekly Recap: Will West Fraser Timber Co Ltd stock see PE expansionTrade Volume Report & Growth-Oriented Investment Plans - moha.gov.vn
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares - MarketBeat
TScan Therapeutics Earnings Notes - Trefis
How TScan Therapeutics Inc. stock reacts to oil pricesTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда
Is TScan Therapeutics Inc. stock safe for conservative investorsJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - DonanımHaber
Will TScan Therapeutics Inc. stock see PE expansionEarnings Miss & Community Consensus Stock Picks - DonanımHaber
TScan Therapeutics, Inc.(NasdaqGM: TCRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event By Investing.com - Investing.com South Africa
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event - Investing.com Canada
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial - MSN
TScan Therapeutics : ASH 2025 Virtual KOL Presentation - marketscreener.com
Wall Street analysts’ outlook for Tscan Therapeutics Inc (TCRX) - setenews.com
TCRX: TSC-101 shows durable efficacy and safety, with pivotal trial and market expansion set for next year - TradingView
TCRX: TSC-101 shows durable efficacy, safety, and $1.4B+ U.S. market potential in AML/MDS - TradingView — Track All Markets
Investor MeetingKey Opinion Leader - marketscreener.com
TScan Therapeutics Reports Promising Two-Year Relapse-Free Survival Data for TSC-101 in Phase 1 Trial for Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces Positive Updated Data from the - GlobeNewswire
How Low Can TScan Therapeutics Stock Really Go? - Trefis
TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Is TScan Therapeutics Stock Built to Withstand a Pullback? - Trefis
Tscan Therapeutics Inc Azioni (TCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):